For the benefit of patients

We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives.

Read more

We are committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

News

News Archive

 

Apr 12. 2019
Basilea reports isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Read more
Apr 12. 2019
Basilea berichtet über Präsentationen zu Isavuconazol (Cresemba®) und Ceftobiprol (Zevtera®) auf dem Europäischen Kongress für Klinische Mikrobiologie und Infektionskrankheiten (ECCMID)
Read more
Apr 10. 2019
Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting
Read more
Apr 10. 2019
Basilea-Aktionäre genehmigen an der Generalversammlung alle Anträge des Verwaltungsrats
Read more

Annual Report 2018

Download English
Download German

Report Archive

CEO Statement

For the benefit of patients around the world, we are continuing to establish Cresemba and Zevtera as truly global brands. In addition, by strengthening our pre-clinical and clinical oncology pipeline, we aim to become a leading provider of innovative cancer therapies in the future.

Facts & Figures

  • 225 employees from 14 countries
  • Headquartered in Basel, Switzerland
  • Focus on oncology and anti-infectives
  • Two products on the market
  • Commercialization partnerships for > 100 countries